Introducing groundbreaking treatment
solutions for patients with aortic heart
valve disease

Learn more

The InFlow Valve

Trascatheter aortic valve implantation (TAVI) is a well-established method of treatment of aortic stenosis. Let us introduce you to our new transcatheter aortic heart valves – one made with biological porcine material and one with biocompatible polymers. Both variants are characterized by high biocompatibility and low risk of calcification (proven in preclinical setting). An innovative method of combining aortic valve components allowed us to enhance the durability of the valves.

  • 1

    Unique materials

    New composite synthetic material and unique biological tissue preventing thrombosis and degeneration of the new valve.

  • 3

    Simplified TAVI procedure

    Atraumatic delivery system for safe implantation and self-positioning of the valve.

  • 2

    Proprietary industrial design

    Formation of the valve leaflets from a sleeve made of porcine pericardium or woven synthetic material.

  • 4

    Proven technology

    Feasible TAVI with delivery system, extensively tested in large animal models.

About Us

about us
Aligning medicine, science and business experience to change the way valve diseases are treated

We are a passionate team of physicians, engineers and business professionals with decades of experience in interventional cardiology, heart surgery and medical device development and market introduction. We believe that our InFlow valves will change the way aortic valve disease is treated worldwide.

Lear more

Projects & Grants

  • successful grant application

    Feng Smart Path

    Non-dilutive, non-returnable funding of EUR 7.1M (PLN 31.8M) granted by the Polish Agency for Enterprise Development (PARP) within the SMART PATH programme in December 2023 .

    Read more
  • successful grant application

    Feng Seal of Excellence

    Seal of Excellence awarded by the European Innovation Council in the EIC Accelerator competition, which resulted in non-dilutive, non-returnable funding of EUR 2.5M (PLN 11.3M) granted by the National Centre for Research and Development (NCBR) in February 2024.

    Read more